International Journal of Clinical Pharmacy

, Volume 41, Issue 6, pp 1398–1399 | Cite as

Treatment of nosocomial infections in intensive care unit with colistin and polymyxin B

  • Anahid Nourian
  • Mona KargarEmail author
Letter to the Editor

To the editor,

We read with interest the article entitled “Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis” by Quintanilha et al. [1]. The study provides valuable data regarding nephrotoxicity, as a known complication of polymyxins (polymyxin B and colistin).

The authors described patients in the neurosurgical, cardiovascular, or transplantation intensive care units (ICUs) who received colistin or polymyxin B for the treatment of documented nosocomial infections. Their results revealed that neither the incidence of nephrotoxicity nor the 30-day mortality rate differed significantly between the patients who received either colistin or polymyxin B. Additionally, they found that colistin was superior to polymyxin B in terms of pharmacoeconomic aspects.

The mean rate of nephrotoxicity with polymyxins was reported to be as high as 32% based on the Acute Kidney Injury Network (AKIN) criteria [2]. Despite their...




Conflicts of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Quintanilha JCF, da Costa Duarte N, Lloret GR, Visacri MB, Mattos KPH, Dragosavac D, et al. Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis. Int J Clin Pharm. 2019;41(1):74–80.CrossRefGoogle Scholar
  2. 2.
    Nation RL, Rigatto MHP, Falci DR, Zavascki AP. Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiotics. 2019;8(1):24.CrossRefGoogle Scholar
  3. 3.
    Min KL, Son ES, Kim JS, Kim SH, Jung SM, Chang MJ. Risk factors of colistin safety according to administration routes: intravenous and aerosolized colistin. PLoS ONE. 2018;13(11):e0207588.CrossRefGoogle Scholar
  4. 4.
    Mendes CA, Cordeiro JA, Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother. 2009;43(12):1948–55.CrossRefGoogle Scholar
  5. 5.
    Okoduwa A, Ahmed N, Guo Y, Scipione MR, Papadopoulos J, Eiras DP, et al. Nephrotoxicity associated with intravenous polymyxin B once-versus twice-daily dosing regimen. Antimicrob Agents Chemother. 2018;62(8):e00025-18.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Clinical Pharmacy, Faculty of PharmacyTehran University of Medical SciencesTehranIran
  2. 2.Research Center for Rational Use of DrugsTehran University of Medical SciencesTehranIran

Personalised recommendations